TIPS Combined With Variceal Embolization for the Prevention of Variceal Rebleeding in Patients With Cirrhosis

Overview

The purpose of this study is to determine whether TIPS combined with variceal embolization are effective in the prevention of variceal rebleeding in patients with liver cirrhosis.

Full Title of Study: “Transjugular Intrahepatic Portosystemic Shunt (TIPS) Using Covered Stents Combined With Variceal Embolization in the Prevention of Variceal Rebleeding for Patients With Cirrhosis : a Prospective, Open-labeled, Randomized, Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 20, 2020

Detailed Description

Variceal bleeding is one of the leading causes of death in patients with cirrhosis. Patients with cirrhosis surviving a variceal bleeding are at high risk of rebleeding (over 60% at 1 year), and mortality from each rebleeding episode is about 20%. Placement of TIPS is a well-established technique that is highly effective in preventing recurrent variceal bleeding, especially if the TIPS is created with an expanded polytetrafluoroethylene (ePTFE)-covered stent, which has a significantly lower risk of shunt dysfunction than does TIPS created with bare stents. But the risk of hepatic encephalopathy greatly increases and the risk of recurrent variceal bleeding after TIPS placement remains an issue. Besides an insufficient decrease in portosystemic pressure gradient after TIPS creation alone, fragile variceal vessels also are considered a risk factor for recurrent bleeding. Accordingly, TIPS combined with variceal embolization has been advocated to achieve the best result possible in preventing recurrent variceal bleeding. However, in recent American Association of the Study of Liver Disease (AASLD) practice guidelines and Baveno V consensus, no treatment strategies were clearly recommended maybe because the exact efficacy of this strategy remains unclear and high-quality randomized controlled trials still lacks. So the investigators hypothesized that embolization of these collateral vessels may increase the blood flow within the shunt and into the liver, which can theoretically decrease the incidence of shunt dysfunction and encephalopathy, even can prolong the patients' survival.

Interventions

  • Procedure: TIPS
    • TIPS will be performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
  • Procedure: Variceal Embolization
    • Embolization of gastroesophageal collaterals will be conducted via the same jugular vein before TIPS implantation. The major procedures includ (a) angiography of gastroesophageal collaterals after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of gastroesophageal collaterals with coils of varying diameters, which result in the gastroesophageal collaterals disappearing at postembolization angiography.

Arms, Groups and Cohorts

  • Experimental: TIPS combined with variceal embolization
    • The covered stents will be used for TIPS The gastroesophageal collaterals will be embolized during the procedure of TIPS
  • Active Comparator: TIPS alone
    • The covered stents will be used for TIPS No embolization of any collateral will be performed during TIPS

Clinical Trial Outcome Measures

Primary Measures

  • All-cause rebleeding
    • Time Frame: 2 years

Secondary Measures

  • Variceal rebleeding
    • Time Frame: 2 years
  • Shunt dysfunction
    • Time Frame: 2 years
  • Hepatic encephalopathy
    • Time Frame: 2 years
  • Liver function changs
    • Time Frame: 2 years
  • Mortality
    • Time Frame: 2 years
  • Adverse events
    • Time Frame: 2 years

Participating in This Clinical Trial

Inclusion Criteria

  • Signed written informed consent – Dignosis of cirrhosis (clinical or by liver biopsy) – Admission due to variceal bleeding occurred 5 to 42 days prior and standard treatment for secondary prophylaxis failed – Age 18 to 75 years Exclusion Criteria:

  • Hepatic carcinoma and/or other malignancy diseases – Portal vein thrombosis (≥50% of the lumen) – Child-Pugh score>13 points – Spontaneous recurrent hepatic encephalopathy – Budd-Chiari syndrome – Large spontaneous portosystemic shunts – Sepsis – Spontaneous bacterial peritonitis – Uncontrollable hypertension – Serious cardiac or pulmonary dysfunction – Renal failure – With TIPS contraindications – Previous TIPS or collateral embolization, – Pregnancy or breast-feeding – History of organ transplantation

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Air Force Military Medical University, China
  • Provider of Information About this Clinical Study
    • Principal Investigator: Guohong Han, M.D., Ph.D. – Air Force Military Medical University, China
  • Overall Official(s)
    • Guohong Han, PhD & MD, Principal Investigator, Xijing Hospital of Digestive Diseases, Fourth Military Medical University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.